World’s first non-contact medically approved sleep monitor able to pre-diagnose sleep apnea uses Novelda XeThru sensor technolog

Oslo, Norway, July 25 2017 – With an increasing number of people experiencing sleep related problems, finding home monitoring solutions which also give accurate results has been a challenge. Sleep monitors available today for the general consumer are not precise enough to correctly analyze sleep patterns. Currently the diagnosis of severe sleeping disorders like sleep apnea uses polysomnography (PSG) equipment that is bulky, uncomfortable, and may affect the patient’s sleep quality. Until now, the use of a non-contact method to measure sleep apnea has not been possible.

Shanghai Megahealth has developed the world’s first non-contact sleep monitoring system that not only measures the amount of sleep and its quality, but also the medical parameter Apnea–Hypopnea Index (AHI) that is used to indicate the severity of sleep apnea.

“Finding the right technology partner was critical to our development,” says Wang Jian Jun, COO of Shanghai Megahealth. “We found a few sensor solutions available that can do non-contact vital signs monitoring but they all have severe limitations. Novelda however, with its unique UWB impulse radarsensor technology, has effectively overcome all these limitations. Combined with Megahealth’s own medical-grade hardware system and patented analysis algorithm, the M+ Sleep Monitoring system accurately measures respiration rate, respiration amplitude, whole body movement, sleep time, sleep cycles and AHI”.

In the US, sleep apnea syndrome is estimated to affect about 4% of men and 2% of women. The complications of sleep apnea include high blood pressure, heart disease, diabetes, daytime sleepiness as well as difficulty concentrating, thinking and remembering. As AHI is a medical parameter, only medical grade equipment with proven accuracy and safety is allowed to measure this index.

“The fact that Megahealth’s M+ Sleep system built on Novelda’s XeThru sensors has received medical approval is testimony not only to the accuracy of our sensor technology but also to the fact that our radar sensors are 100% safe.”
says Bjørn Åge Brandal, Novelda’s VP of sales and marketing in Asia, continuing “We are very excited to see the first of many non-contact vital signs monitoring solutions enabled by our sensor technology now entering the market.”

The M+ sleep monitoring solution is available now and can be purchased directly from Shanghai Megahealth.

+++ ends +++

For further information and reader enquiries:
Bjørn Åge Brandal, Novelda AS, 21/F The Center, 99 Queen’s Road Central, Hong Kong
Tel: +852 3478 3860

Wang Jian Jun, Shanghai Megahealth
Tel: +86-21-60760258;

For editorial information or to discuss feature article opportunities:
Derek Rye, Publitek Limited, 18 Brock Street, Bath, BA1 2LW, United Kingdom
Tel: +44 1225 470 000
Fax: +44 1225 470 047

About Novelda AS
Novelda AS is a leading developer, manufacturer and distributor of smart sensor technology for detecting vital signs, motion, presence and location. Novelda´s XeThru sensors can improve quality of life and personal comfort and safety by enabling non-intrusive sensors that collect important data while
preserving full privacy. The XeThru technology can also be used in a number of automotive and industrial applications. The sensors use extremely low energy GHz radio waves and advanced signal processing, which makes them highly suited to a range of applications. Novelda provides both development kits and
OEM modules to system developers worldwide.

About Megahealth
Megahealth was founded in Shanghai in 2014 and is focusing on intelligent medical detection products and develops personal health management solutions. Customers include patients, hospitals, insurance companies, enterprises and government. Megahealth have set up a joint laboratory with
Zhejiang University, focusing on advanced medical equipment. The team includes top medical scientists, clinical engineering specialists and R&D engineers.



xethru-logo-boxed-purple View original link ›